MX2010002680A - Uso de derivados de purina para la manufactura de un medicamento. - Google Patents

Uso de derivados de purina para la manufactura de un medicamento.

Info

Publication number
MX2010002680A
MX2010002680A MX2010002680A MX2010002680A MX2010002680A MX 2010002680 A MX2010002680 A MX 2010002680A MX 2010002680 A MX2010002680 A MX 2010002680A MX 2010002680 A MX2010002680 A MX 2010002680A MX 2010002680 A MX2010002680 A MX 2010002680A
Authority
MX
Mexico
Prior art keywords
medicament
manufacture
purine derivatives
apoptosis
purine
Prior art date
Application number
MX2010002680A
Other languages
English (en)
Spanish (es)
Inventor
Laurent Meijer
Karima Bettayeb
Herve Galons
Nassima Oumata
Christian Berthou
Karine Lester
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of MX2010002680A publication Critical patent/MX2010002680A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010002680A 2007-09-12 2008-09-12 Uso de derivados de purina para la manufactura de un medicamento. MX2010002680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
PCT/FR2008/001278 WO2009068761A2 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Publications (1)

Publication Number Publication Date
MX2010002680A true MX2010002680A (es) 2010-08-26

Family

ID=39382006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002680A MX2010002680A (es) 2007-09-12 2008-09-12 Uso de derivados de purina para la manufactura de un medicamento.

Country Status (13)

Country Link
US (1) US8431583B2 (enExample)
EP (1) EP2187889B1 (enExample)
JP (1) JP5485893B2 (enExample)
KR (1) KR20100075908A (enExample)
CN (1) CN101918000B (enExample)
BR (1) BRPI0816810A2 (enExample)
CA (1) CA2699590A1 (enExample)
DK (1) DK2187889T3 (enExample)
ES (1) ES2444419T3 (enExample)
FR (1) FR2920776B1 (enExample)
MX (1) MX2010002680A (enExample)
RU (1) RU2500400C2 (enExample)
WO (1) WO2009068761A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament

Also Published As

Publication number Publication date
ES2444419T3 (es) 2014-02-25
KR20100075908A (ko) 2010-07-05
DK2187889T3 (da) 2014-02-03
BRPI0816810A2 (pt) 2017-05-16
RU2500400C2 (ru) 2013-12-10
CA2699590A1 (fr) 2009-06-04
WO2009068761A3 (fr) 2010-01-07
RU2010108505A (ru) 2011-10-20
FR2920776A1 (fr) 2009-03-13
CN101918000B (zh) 2012-11-21
EP2187889A2 (fr) 2010-05-26
CN101918000A (zh) 2010-12-15
US20100311768A1 (en) 2010-12-09
EP2187889B1 (fr) 2013-11-06
JP2010539146A (ja) 2010-12-16
JP5485893B2 (ja) 2014-05-07
FR2920776B1 (fr) 2012-09-28
WO2009068761A2 (fr) 2009-06-04
US8431583B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
BR112012002134B8 (pt) compostos inibidores de apaf-1
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
NZ615270A (en) Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
PH12013501600A1 (en) Novel heterocyclic derivatives
BR112012008019A2 (pt) derivados de purina úteis como inibidores de hsp90
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
EA201000098A1 (ru) Производные хиназолинамида
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MA32505B1 (fr) 5-alcynyl-pyrimidines
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2010002680A (es) Uso de derivados de purina para la manufactura de un medicamento.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors
TN2011000530A1 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration